On January 7, 2021 Shasqi, a clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies, reported that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday January 13th at 2:00pm Eastern Time (Press release, Shasqi, JAN 7, 2021, View Source [SID1234573664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Mejia Oneto’s presentation will be available as a live webcast through the JP Morgan conference portal and an archived recording will be made available after the conference.

Shasqi is currently advancing its lead clinical candidate, SQ3370, a click-activated protodrug therapy, in a phase 1 clinical trial. SQ3370 is the first click chemistry-based treatment to be tested in humans. That study, SQ3370-001, is currently enrolling patients with advanced sarcomas and other solid tumors in the United States and Australia (ClinicalTrials.gov Identifier NCT04106492). The company presented pre-clinical and trial-in-progress data from the SQ3370 program in late 2020. Those presentations are available on www.shasqi.com.

CAPAC and SQ3370
SQ3370 utilizes Shasqi’s proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform, a click chemistry-based approach that activates cancer drugs at a specific tumor with minimal systemic toxicity. The platform utilizes the biocompatible chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected into the target tumor lesion, where it precisely captures and activates an infused protodrug. Unlike targeted therapies, the CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity. CAPAC is highly modular and can be applied to a wide variety of cancer therapeutics.

On January 7, 2021 ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, reported the completion of its previously announced underwritten public offering of 11,856,500 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $57.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay (Press release, ViewRay, JAN 7, 2021, View Source [SID1234573663]). All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriter’s option to purchase additional shares.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.

Piper Sandler & Co. acted as the sole book-running manager for the offering. B. Riley Securities, Inc. and Oppenheimer & Co. Inc. acted as co-managers for the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and became effective on February 7, 2019. This offering was made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website located at View Source Alternatively, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

On January 7, 2021 Apexigen, Inc., a clinical-stage biopharmaceutical company, reported that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor healthcare conferences (Press release, Apexigen, JAN 7, 2021, View Source [SID1234573662]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Solebury Trout Virtual Management Access Event being held January 6 – 15, 2021. The Company will be conducting one-on-one meetings.
H.C. Wainwright Virtual BioConnect 2021 Conference. The Company’s presentation will be available on-demand from January 11 – 14, 2021.

On January 7, 2021 Rakuten Medical, Inc. (RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox, reported that it will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021 (Press release, Rakuten Medical, JAN 7, 2021, View Source [SID1234573661]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rakuten Medical’s Chairman and CEO, Hiroshi "Mickey" Mikitani, is scheduled to present virtually at approximately 4:30 a.m. PST, Monday, January 11. A live audio webcast of the presentation can be accessed by following this link. Following the completion of the presentation, a full audio recording will be available in the News section of the Rakuten Medical, Inc website at www.rakuten-med.com and will be archived in this location for 30 days.

On January 7, 2021 Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer, reported the pricing of its initial public offering of 11,000,000 American Depositary Shares ("ADSs"), each representing five ordinary shares, at a public offering price of US$19.00 per ADS (Press release, Gracell Biotechnologies, JAN 7, 2021, View Source [SID1234573660]). The gross proceeds to Gracell from the offering are expected to be US$209.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Gracell has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 ADSs at the initial public offering price, less underwriting discounts and commissions. All of the ordinary shares represented by ADSs are being offered by Gracell.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ADSs have been approved for listing on The Nasdaq Global Market and are expected to begin trading on January 8, 2021 under the ticker symbol "GRCL". The offering is expected to close on January 12, 2021 subject to the satisfaction of customary closing conditions.

Citigroup, Jefferies, Piper Sandler & Co. and Wells Fargo Securities are acting as joint book-running managers for the offering.

The offering of the securities is made only by means of a prospectus forming a part of the effective registration statement. A copy of the prospectus relating to the offering may be obtained by contacting: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146 or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected]; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, NY 10001, by telephone at (800) 326-5897 or by email at [email protected].

Gracell’s registration statement relating to the offering has been filed with, and declared effective by the U.S. Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.